Register Login

FDA Approves Pradaxa for Children

Thanks to Dean Willett, Precision BioLogic Inc., for today’s heads-up for this FDA announcement [click] approving dabigatran etixalate [Pradaxa®] therapy for children 3 months–12 years who have experienced venous thromboembolic disease.

Comments (0)
Anticoagulant Therapy

No comments here.

Leave a Reply